I have now had the chance to view both the SPL webinar and the ****** review.
Clearly we do not know the drug or the antibody which Petalion has identified.
We do know that the dendrimer technology works with all taxanes and irinotecan.
It is comforting that this is not a rabbit hunt. It will apply the dendrimer technology to an identified ADC combination and we know that SPL technology has been able to control release (as in AZD 0466) and it works with the drugs in the DEP program. It is also soluble!
So it is a direct challenge to the SPL chemists and their Petalion colleagues to make the package work. Simple answer yes or no! And SPL get paid for their involvement.
The two Petalion folk on the webinar were impressive, in my view. Down to earth and focussed!
And they certainly have a good rack record of selling their results to big pharma.
I have now had the chance to view both the SPL webinar and the...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.44M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.5¢ | 10.5¢ | $132.0K | 1.162M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 535926 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.0¢ | 12.5¢ | 10.5¢ | 991112 | ||
| Last updated 15.53pm 03/05/2024 ? | |||||
| SPL (ASX) Chart |